All In Biotech

Drug Trial Radar · NCT06603870

Secondary Prevention of VTE in Patients With Cancer and Catheter-Related Upper Extremity Deep Vein Thrombosis

Secondary Prevention of Venous Thromboembolism in Patients With Cancer and Catheter-Related Upper Extremity Deep Vein Thrombosis (STREAM-Line Study)

Last checked: Nov 20, 2026Latest source record: Sep 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

330

Planned (sponsor's estimate)

Start

Dec 19, 2024

Primary completion

Oct 2029

Study completion Oct 2029

Sponsor

Lead sponsor
Ottawa Hospital Research InstituteAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Sep 19, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This trial seeks to evaluate a management strategy after the acute treatment duration (≥ 3 months of therapeutic anticoagulation) for patients with cancer and catheter-related upper extremity deep vein thrombosis (DVT).

Conditions

  • Venous Thromboembolism
  • Cancer
  • Upper Extremity Deep Vein Thrombosis
  • Catheter-Related Infections

Interventions

  • Anticoagulation TherapyDrug

    Patients will be enrolled after at least 3 months of therapeutic anticoagulation for an acute catheter-related upper extremity DVT while they are treated with therapeutic anticoagulation as standard of care. After enrollment, patients will be managed with prophylactic dose of anticoagulation as long as either a CVC or active cancer is present. If cancer goes into remission, at the time of CVC removal, anticoagulation will be stopped, but patients will continue to be followed until the end of the study at 6 months.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Venous Thromboembolism (VTE) RateTime frame: 6 months

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • The Ottawa Hospital

    Ottawa, Ontario, Canada · Recruiting

  • Sault Area Hospital

    Sault Ste. Marie, Ontario, Canada · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.